Aducanumab: evidence from clinical trial data and controversies

Aducanumab: evidence from clinical trial data and controversies

Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first dise...

Full description

Bibliographic Details
Main Authors: Rajesh R Tampi, Brent P Forester, Marc Agronin
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2021-10-01
Series:Drugs in Context
Subjects:
β-amyloid
aducanumab
alzheimer’s disease
amyloid-related imaging abnormalities
anti-aβ monoclonal antibody
dementia
neurofibrillary tangles
tau proteins
Online Access:https://www.drugsincontext.com/aducanumab-evidence-from-clinical-trial-data-and-controversies

Internet

https://www.drugsincontext.com/aducanumab-evidence-from-clinical-trial-data-and-controversies

Similar Items